Entrada Therapeutics, Inc.
TRDA
$6.37
$0.111.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -96.67% | -87.94% | -71.42% | -66.80% | 5.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.67% | -87.94% | -71.42% | -66.80% | 5.74% |
| Cost of Revenue | 9.92% | 12.18% | 17.91% | 21.14% | 22.19% |
| Gross Profit | -412.58% | -234.71% | -184.38% | -142.99% | -24.42% |
| SG&A Expenses | 3.46% | 6.20% | 11.01% | 17.83% | 16.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.41% | 10.78% | 16.28% | 20.35% | 20.82% |
| Operating Income | -4,396.76% | -431.83% | -310.37% | -202.90% | -82.69% |
| Income Before Tax | -793.67% | -314.82% | -236.73% | -169.68% | -41.22% |
| Income Tax Expenses | 198.97% | 7.57% | -104.83% | -159.88% | -105.71% |
| Earnings from Continuing Operations | -770.34% | -319.04% | -288.27% | -170.23% | 5.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -770.34% | -319.04% | -288.27% | -170.23% | 5.52% |
| EBIT | -4,396.76% | -431.83% | -310.37% | -202.90% | -82.69% |
| EBITDA | -2,286.19% | -399.11% | -291.44% | -195.24% | -70.73% |
| EPS Basic | -559.57% | -274.09% | -248.92% | -157.68% | 24.43% |
| Normalized Basic EPS | -557.37% | -267.00% | -208.41% | -157.27% | -29.02% |
| EPS Diluted | -600.91% | -282.63% | -257.40% | -160.55% | 26.24% |
| Normalized Diluted EPS | -593.09% | -274.76% | -212.79% | -159.33% | -31.23% |
| Average Basic Shares Outstanding | 6.07% | 10.95% | 16.26% | 22.00% | 17.56% |
| Average Diluted Shares Outstanding | 3.73% | 7.47% | 15.68% | 19.97% | 17.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |